We are live on
!
Find out more
PIM
Partner Investment Management Portfolio holdings
AUM
$13.9M
1-Year Est. Return
55.92%
This Fund
S&P 500
This Quarter
Est. Return
+23.93%
1 Year Est. Return
+55.92%
3 Year Est. Return
+168.07%
5 Year Est. Return
+301.91%
10 Year Est. Return
–
AUM
$86.5M
AUM Growth
+$6.47M
(+8.1%)
Cap. Flow
-$1.87M
Cap. Flow
% of AUM
-2.16%
Top 10 Holdings %
Top 10 Hldgs %
33.2%
Holding
120
New
33
Increased
16
Reduced
36
Closed
30
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Stryker
SYK
|
+$2.09M |
| 2 |
AGN
Allergan plc
AGN
|
+$1.67M |
| 3 |
WCG
Wellcare Health Plans, Inc.
WCG
|
+$1.52M |
| 4 |
Pfizer
PFE
|
+$1.42M |
| 5 |
UnitedHealth
UNH
|
+$1.12M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ALLK
Allakos
ALLK
|
+$4.3M |
| 2 |
UBX
Unity Biotechnology
UBX
|
+$3.43M |
| 3 |
NTGN
Neon Therapeutics, Inc. Common Stock
NTGN
|
+$2.48M |
| 4 |
Blackrock
BLK
|
+$1.71M |
| 5 |
GoDaddy
GDDY
|
+$1.69M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 46.46% |
| 2 | Technology | 17.92% |
| 3 | Communication Services | 6.41% |
| 4 | Consumer Discretionary | 5.03% |
| 5 | Financials | 1.87% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
101
CALL
iShares S&P 100 ETF
OEF
$20.5B
| – | – |
-68,100
| Closed | -$2.66M |
|
102
LiveRamp
RAMP
$2.3B
| – | – |
-5,763
| Closed | -$223K |
|
103
Arcus Biosciences
RCUS
$3.64B
| – | – |
-1,575
| Closed | -$17K |
|
104
Solid Biosciences
SLDB
$900M
| – | – |
-817
| Closed | -$328K |
|
105
StoneCo
STNE
$2.58B
| – | – |
-2,289
| Closed | -$42K |
|
106
Zai Lab
ZLAB
$2.62B
| $0 | ﹤0.01% |
+6
| New | +$164 |
|
107
Zscaler
ZS
$27.3B
| – | – |
-1,258
| Closed | -$49K |
|
|
TECX
108
Tectonic Therapeutic
TECX
$606M
| – | – |
-137
| Closed | -$27K |
|
|
MRNS
109
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
| – | – |
-784
| Closed | -$9K |
|
|
VRAY
110
DELISTED
ViewRay, Inc.
VRAY
| – | – |
-21,604
| Closed | -$131K |
|
|
ACOR
111
CALL
DELISTED
Acorda Therapeutics
ACOR
| – | – |
-174
| Closed | -$326K |
|
|
ACOR
112
DELISTED
Acorda Therapeutics
ACOR
| – | – |
-109
| Closed | -$204K |
|
|
AERI
113
DELISTED
Aerie Pharmaceuticals
AERI
| – | – |
-22,559
| Closed | -$814K |
|
|
PLAN
114
DELISTED
Anaplan, Inc.
PLAN
| – | – |
-889
| Closed | -$24K |
|
|
CBLK
115
DELISTED
Carbon Black, Inc. Common Stock
CBLK
| – | – |
-6,163
| Closed | -$83K |
|
Similar funds
SWM
ACM
ECAU
SL
DII
FIM
EM
BHC
Partner Investment Management's Q1 2019 Portfolio in Review
As of Q1 2019, Partner Investment Management held 120 positions worth $86.5M, up 8.1% from $80.1M the previous quarter. Its ten largest holdings account for 33% of the portfolio.
Partner Investment Management's Q1 2019 filing shows 33 new, 16 increased, 36 reduced and 30 closed positions. Its largest new stake was Stryker: 11,607 shares worth $2.29M. The largest sale was Allakos, an estimated $4.3M.
By sector, the portfolio is most concentrated in Healthcare at 46% of assets, down from 54% a quarter earlier, followed by Technology and Communication Services.
- Partner Investment Management's largest Q1 2019 buy was Stryker: 11,607 shares worth $2.29M.
- Partner Investment Management added most to Pfizer in Q1 2019, an estimated $1.42M increase.
- Partner Investment Management's biggest Q1 2019 reduction was Unity Biotechnology, cutting an estimated $3.43M.
- Partner Investment Management fully exited Allakos in Q1 2019, selling an estimated $4.3M.
- Partner Investment Management's ten largest holdings make up 33% of its $86.5M portfolio in Q1 2019.
- Partner Investment Management opened 33 new positions and closed 30 in Q1 2019.
- Partner Investment Management's portfolio value rose 8.1% quarter-over-quarter to $86.5M.
Based on Partner Investment Management's 13F filing for Q1 2019, filed 15 May 2019.